Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study

被引：0
|
作者：
Jun Guo
Yiran Huang
Xu Zhang
Fangjian Zhou
Yinghao Sun
Shukui Qin
Zhangqun Ye
Hui Wang
Annette Jappe
Patrick Straub
Nicoletta Pirotta
Sven Gogov
机构：
[1] Peking University Cancer Hospital and Institute,
[2] Shanghai Renji Hospital,undefined
[3] The General Hospital of PLA,undefined
[4] Sun Yat-sen University Cancer Center,undefined
[5] Shanghai Changhai Hospital,undefined
[6] Nanjing Bayi Hospital,undefined
[7] Wuhan Tongji Hospital,undefined
[8] Beijing Novartis Pharma Company,undefined
[9] Ltd.,undefined
[10] Novartis Pharma AG,undefined
[11] Novartis Pharma AG,undefined
[12] Novartis Pharma AG,undefined
[13] Novartis Pharma AG,undefined
来源：
BMC Cancer | / 13卷
关键词：
Asian; Everolimus; mTOR inhibitor; Renal cell cancer; Sunitinib; Sorafenib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
    Ana M. Molina
    Thomas E. Hutson
    James Larkin
    Anne M. Gold
    Karen Wood
    Dave Carter
    Robert Motzer
    M. Dror Michaelson
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 181 - 189
  • [32] Sarcomatoid Dedifferentiation in Metastatic Clear Cell Renal Cell Carcinoma and Outcome on Treatment With Anti-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Retrospective Analysis
    Beuselinck, Benoit
    Lerut, Evelyne
    Wolter, Pascal
    Dumez, Herlinde
    Berkers, Johannes
    Van Poppel, Hendrik
    Joniau, Steven
    Oyen, Raymond
    De Wever, Liesbeth
    Strijbos, Michiel
    Paridaens, Robert
    Schoffski, Patrick
    CLINICAL GENITOURINARY CANCER, 2014, 12 (05) : E205 - E214
  • [33] A Phase 2, Single-Arm Study of Ramucirumab in Patients With Metastatic Renal Cell Carcinoma With Disease Progression on or Intolerance to Tyrosine Kinase Inhibitor Therapy
    Garcia, Jorge A.
    Hudes, Gary R.
    Choueiri, Toni K.
    Stadler, Walter M.
    Wood, Laura S.
    Gurtler, Jayne
    Bhatia, Shailender
    Joshi, Adarsh
    Hozak, Rebecca R.
    Xu, Yihuan
    Schwartz, Jonathan D.
    Thompson, John A.
    CANCER, 2014, 120 (11) : 1647 - 1655
  • [34] Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer
    Kato, Taigo
    Mizuno, Ryuichi
    Miyake, Hideaki
    INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (05) : 465 - 474
  • [35] TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third -line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma
    Verzoni, Elena
    Grassi, Paolo
    Montone, Rosanna
    Galli, Giulia
    Necchi, Andrea
    Procopio, Giuseppe
    TUMORI JOURNAL, 2015, 101 (06): : 701 - 703
  • [36] A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1,-2, and-3 tyrosine kinases in Chinese patients with advanced solid tumors
    Cao, Junning
    Zhang, Jian
    Peng, Wei
    Chen, Zhiyu
    Fan, Songhua
    Su, Weiguo
    Li, Ke
    Li, Jin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 259 - 269
  • [37] A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors
    Beckermann, Kathryn E.
    Bestvina, Christine M.
    El Osta, Badi
    Sanborn, Rachel E.
    Borghaei, Hossein
    Lammers, Philip Edward
    Selvaggi, Giovanni
    Whisenant, Jennifer G.
    Heimann-Nichols, Ellen
    Berry, Lynne
    Hsu, Chih-Yuan
    Shyr, Yu
    Horn, Leora
    Wakelee, Heather
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (02):
  • [38] Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma
    Busch, Jonas
    Seidel, Christoph
    Goranova, Irena
    Erber, Barbara
    Peters, Robert
    Friedersdorff, Frank
    Magheli, Ahmed
    Miller, Kurt
    Gruenwald, Viktor
    Weikert, Steffen
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (03) : 563 - 569
  • [39] The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study
    Iinuma, Koji
    Yamada, Toyohiro
    Kameyama, Koji
    Taniguchi, Tomoki
    Kawada, Kei
    Ishida, Takashi
    Nagai, Shingo
    Enomoto, Torai
    Ueda, Shota
    Takagi, Kimiaki
    Kawase, Makoto
    Takeuchi, Shinichi
    Kawase, Kota
    Kato, Daiki
    Takai, Manabu
    Nakane, Keita
    Koie, Takuya
    CANCERS, 2023, 15 (03)
  • [40] Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study
    Kadono, Yoshifumi
    Konaka, Hiroyuki
    Nohara, Takahiro
    Izumi, Kouji
    Anai, Satoshi
    Fujimoto, Kiyohide
    Koguchi, Tomoyuki
    Ishibashi, Kei
    Kawai, Noriyasu
    Nakane, Keita
    Iba, Akinori
    Masumori, Naoya
    Takahara, Shizuko
    Mizokami, Atsushi
    CANCERS, 2023, 15 (10)
12345